Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT04778917Phase 4
Key facts
Phase 4, randomised, single-blind trial of low molecular weight heparin calcium in pneumonia (4 arms), sponsored by Capital Institute of Pediatrics. Primary endpoints: Lung imaging absorption improvement time after treatment at 1 month, Time to improve cough symptoms at 2 weeks and 2 more. Started Dec 2014; status: completed.
Conventional (High D-dimer)
Conventional treatment without LMWH in patients with D-dimer >= 500 ug/L.
Low Dose LMWH
LMWH Calcium 50-100 units/kg/day in patients with D-dimer >= 500 ug/L.
High Dose LMWH
LMWH Calcium 200 units/kg/day (100 units/kg BID) in patients with D-dimer >= 500 ug/L.
Conventional (Low D-dimer)
Conventional treatment in patients with D-dimer < 500 ug/L.
Children aged 28 days to 18 years with a clinical diagnosis of simple pneumonia. Patients with congenital heart disease, kidney disease, blood system diseases, paralysis, muscle tension, fracture, family history of thrombotic disease, indwelling central venous catheters, parenteral nutrition, neoplastic disease, or primary immunodeficiency disease are excluded.
Lung imaging absorption improvement time after treatment
Time to improve cough symptoms
Heat retreat time
The time to disappear rhonchus in the lungs
Average hospital stay time
The degree of coagulation improvement
Differences in inflammation indicators in each group
Beyond the preview
Full results, competitive context and analysis are in the Gosset platform.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT04778917.